Every 10-Q that Fortress Biotech, Inc. (FBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBIO filings page.
Fortress Biotech, Inc. reported consolidated net income of $137.8 million for the six months ended June 30, 2026, driven primarily by a $158.9 million gain on the sale of a Rare Pediatric Disease priority review voucher at subsidiary Cyprium. Net revenue for the period was $34.8 million, while total operating expenses of $52.5 million produced a loss from operations of $17.7 million, indicating that core operations remain unprofitable.
Cash and cash equivalents rose to $196.6 million at June 30, 2026 from $79.4 million at year-end 2025, supported by $144.6 million of net cash provided by operating activities. Total assets increased to $316.7 million, and total stockholders’ equity to $206.1 million, partly reflecting the Cyprium dividend and fair value gains on equity investments. Notes payable, net, declined to $39.6 million, and the company was in compliance with covenants under both the Oaktree and SWK credit facilities.
Management states that $153.8 million of cash and cash equivalents at the parent entity level is considered sufficient to fund operations for at least twelve months after the report date, though additional capital may be needed for development programs and strategic growth. Dividends on the 9.375% Series A preferred stock remain paused and cumulative undeclared dividends totaled about $16.0 million as of June 30, 2026.
Fortress Biotech reported a sharp turnaround to profitability driven by a major asset sale. For the quarter ended March 31, 2026, net revenue rose to $16.0 million, mainly from dermatology product sales at Journey Medical.
The key event was Cyprium’s sale of a Rare Pediatric Disease priority review voucher for $205 million, generating a gain of $158.9 million and lifting net income attributable to common stockholders to $108.4 million, or $3.44 basic EPS. Cash and cash equivalents jumped to $255.8 million, and total assets nearly doubled to $356.9 million, while long-term notes payable, net, declined to $39.4 million after prepayments on the Oaktree facility. Management states that Parent Entity cash of $209.9 million is sufficient to fund operations for at least 12 months, although the company still expects operating losses over the next several years and may pursue additional financings.
Fortress Biotech (FBIO) filed its Q3 2025 10‑Q, showing higher sales and a swing to quarterly profitability aided by non-operating gains. Net revenue was $17.6 million versus $14.6 million a year ago, while loss from operations was $6.8 million. Other income of $15.7 million drove net income of $8.8 million; income attributable to Fortress was $5.9 million and net income to common stockholders was $3.7 million (diluted EPS $0.11).
Year to date, net revenue reached $47.2 million and the company recorded a $27.1 million gain from deconsolidating Checkpoint after its sale to Sun Pharma, plus $2.6 million other income tied to Urica’s Crystalys transaction. Cash and cash equivalents were $86.2 million, up from $57.3 million at year‑end, as financing and investing inflows offset operating cash use of $53.2 million.
Total liabilities fell to $116.2 million and total stockholders’ equity improved to $65.2 million. Common shares outstanding were 31,037,937 as of November 10, 2025. The filing states Parent Entity cash of $38.6 million is sufficient for at least 12 months following the filing date.